Vaxcyte, Inc. PCVX
Set alert
62.03 USD -0.58 -0.93%
At close
62.53 +0.50 +0.81%
Pre-market · Nov 2, 7:07 AM ET
61.02 Day range 63.28
39.87 52-week range 90.75
- YTD
- +34.44%
- 1 year
- +38.61%
- Open
- 62.59
- Prev close
- 62.61
- Mkt cap
- 9.76B
- Vol
- 1.71M
- Avg vol
- 2.08M
- EPS
- -7.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 61.02
- High
- 63.28
- Forward P/E
- -8.71
- Beta
- 1.23
- Short ratio
- 4.40
- Inst. own
- 111.05%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 61.59
- 200-d avg
- 56.97
- 1y target
- 117.30
3M chart
Events in this range
- Aug 5, 2026Earnings: -1.97; estimate -2.06; surprise 4.37%
- Sep 25, 2026Rating: Needham · Buy → Buy
- Sep 28, 2026Rating: B of A Securities · Buy → Buy
- Oct 5, 2026Rating: Guggenheim · Buy → Buy
- Oct 5, 2026Rating: Needham · Buy → Buy
- Oct 5, 2026Rating: BTIG · Buy → Buy
- Oct 12, 2026Rating: Cantor Fitzgerald · Overweight → Overweight
Signals (20)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 29, 2026 | 3 days ago |
| SMA: Bullish | Oct 29, 2026 | 3 days ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 19, 2026 | 1 week ago |
| SMA: Bullish | Oct 5, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 5, 2026 | 3 weeks ago |
| RSI: Overbought | Oct 5, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
Financial health
Altman Z-Score
13.53 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
0 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 2
Valuation
P/E -8.2×
FY 2017 5y median -13.9× FY 2025
P/S 0.0×
FY 2017 5y median 0.0× FY 2025
P/B 2.3×
FY 2017 5y median 3.3× FY 2025
P/FCF -9.4×
FY 2017 5y median -16.7× FY 2025
EV/EBITDA -8.5×
FY 2017 5y median -12.2× FY 2025
EV/Sales 0.0×
FY 2017 5y median 0.0× FY 2025
FCF Yield -10.7%
FY 2017 5y median -6.0% FY 2025
Profitability
Gross Margin 0.0%
FY 2017 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2017 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2017 5y median 0.0% FY 2025
ROE -28.5%
FY 2017 5y median -28.5% FY 2025
ROIC -32.5%
FY 2017 5y median -32.5% FY 2025
ROA -25.2%
FY 2017 5y median -25.2% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2017 FY 2025
Operating Income -62.2%
FY 2017 FY 2025
EPS (diluted) -48.2%
FY 2017 FY 2025
Free Cash Flow -40.9%
FY 2017 FY 2025
Financial Health
Current Ratio 7.9×
FY 2017 5y median 8.9× FY 2025
Quick Ratio 7.9×
FY 2017 5y median 8.9× FY 2025
Debt / Equity 0.1×
FY 2017 5y median 0.0× FY 2025
Net Debt / EBITDA -0.1×
FY 2017 5y median 0.7× FY 2025
Interest Coverage 0.0×
FY 2017 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2017 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2017 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31